Japan and Taiwan in the wake of bio-globalization : drugs, race and standards

This is a study of Japan and Taiwan's different responses to the expansion of the global drug industry. The thesis focuses on the problematic of "voicing," of how a state can make its interests heard in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The ICH is a unique project that facilitates the formation of a single global market by creating universal standards for clinical trials and drug approvals. Tracing, through "slow motion" ethnography, step by step, why Japan claims a racial difference requires additional local clinical trials with "Asian bodies," this thesis rejects conventional interpretations of protectionism for Japan's resistance to globalization. It argues that more than protectionism is involved, and that a rich ethnographic understanding of Japan's medical infrastructure is required to understand the claim of biological, cultural, and national differences, as well as biostatistical arguments about the ambiguities of "extrapolation" of clinical data from one place to another.

Department dc:contributor.department

Massachusetts Institute of Technology. Program in Science, Technology and Society.

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2005

Author dc:creator

• Kuo, Wen-Hua

Advisor dc:contributor.advisor

• Michael M.J. Fischer.

• Program in Science, Technology and Society.

Statement dc:rights

• M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/1721.1/39195

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/39195